Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $95.00

Merck & Co., Inc. (NYSE:MRK) had its price objective increased by Truist from $92.00 to $95.00 in a research report released on Wednesday, The Fly reports. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently commented on MRK. SVB Leerink increased their price objective on shares of Merck & Co., Inc. from $104.00 to $105.00 and gave the company an outperform rating in a research note on Friday, October 22nd. Berenberg Bank restated a hold rating and issued a $92.00 price target (up from $86.00) on shares of Merck & Co., Inc. in a research report on Sunday, October 10th. Zacks Investment Research upgraded shares of Merck & Co., Inc. from a sell rating to a hold rating and set a $82.00 price target for the company in a research report on Tuesday, August 24th. Truist Securities began coverage on shares of Merck & Co., Inc. in a research report on Tuesday, July 27th. They issued a buy rating and a $76.79 price target for the company. Finally, Mizuho began coverage on shares of Merck & Co., Inc. in a research report on Thursday, October 28th. They issued a buy rating and a $99.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Buy and a consensus price target of $95.73.

Shares of NYSE:MRK opened at $82.28 on Wednesday. The company has a market cap of $207.83 billion, a price-to-earnings ratio of 29.07, a PEG ratio of 2.11 and a beta of 0.46. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.31 and a quick ratio of 1.07. The firm has a 50 day simple moving average of $80.47 and a 200 day simple moving average of $78.04. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $91.40.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Wednesday, October 27th. The company reported $1.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.55 by $0.20. The business had revenue of $13.15 billion during the quarter, compared to the consensus estimate of $12.32 billion. Merck & Co., Inc. had a net margin of 14.64% and a return on equity of 48.21%. The firm’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.74 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.76 EPS for the current year.

In other news, insider Kenneth C. Frazier sold 663,881 shares of the stock in a transaction on Tuesday, November 9th. The shares were sold at an average price of $82.26, for a total transaction of $54,610,851.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Caroline Litchfield sold 18,335 shares of the firm’s stock in a transaction on Thursday, November 4th. The stock was sold at an average price of $91.00, for a total transaction of $1,668,485.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 936,784 shares of company stock valued at $78,682,559. 0.32% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the business. Mcdonald Partners LLC lifted its stake in shares of Merck & Co., Inc. by 1.0% in the third quarter. Mcdonald Partners LLC now owns 26,168 shares of the company’s stock valued at $1,965,000 after buying an additional 257 shares in the last quarter. Fortis Advisors LLC lifted its stake in shares of Merck & Co., Inc. by 5.8% in the third quarter. Fortis Advisors LLC now owns 4,319 shares of the company’s stock valued at $324,000 after buying an additional 236 shares in the last quarter. Liontrust Investment Partners LLP bought a new position in shares of Merck & Co., Inc. in the third quarter valued at $454,000. CFS Investment Advisory Services LLC bought a new position in shares of Merck & Co., Inc. in the third quarter valued at $395,000. Finally, Cribstone Capital Management LLC lifted its stake in shares of Merck & Co., Inc. by 24.2% in the third quarter. Cribstone Capital Management LLC now owns 16,455 shares of the company’s stock valued at $1,236,000 after buying an additional 3,207 shares in the last quarter. Institutional investors and hedge funds own 71.79% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Story: Trading on Margin

The Fly logo

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.